滑膜组织特征提升早期炎性关节炎分类与预后及治疗反应预测并预测后续生物制剂需求:PEAC队列结果
PEAC队列纳入200例未经治疗的早期关节炎患者,按1987 ACR标准分类为RA1987或未分化关节炎(UA),UA中再按2010 ACR/EULAR标准分类为RA2010。滑膜活检行免疫组化与基因表达分析显示,RA1987患者疾病活动度、组织学滑膜炎及免疫细胞浸润显著高于RA2010或UA。淋巴-髓系病理类型患者12个月时需生物制剂比例显著更高,将滑膜病理生物学标志物整合入临床预测模型后,生物制剂需求预测性能从78.8%提升至89%-90%。
要点
- RA1987患者滑膜炎症与免疫浸润程度显著高于RA2010或UA。
- 淋巴-髓系病理类型者12个月时需生物制剂比例显著更高。
- 整合滑膜标志物后生物制剂需求预测性能从78.8%升至89%-90%。
核心结论
- 滑膜病理生物学标志物可细化早期临床分类标准,有助于预测疾病结局并按需分层治疗干预。
研究设计与样本
- 200例未经治疗的早期关节炎患者按RA1987或UA分类,UA再按RA2010分类。
- 滑膜组织经微创超声引导活检,行免疫组化与Nanostring基因表达分析。
- 12个月时判定治疗需求(csDMARDs vs 生物制剂 vs 无csDMARDs治疗)。
主要发现
- 128/200例归为RA1987,25例归为RA2010,47例归为UA。
- RA1987患者疾病活动度、组织学滑膜炎、免疫细胞浸润及B/T细胞活化相关基因上调显著高于RA2010或UA。
- RA2010与UA共享相似的临床和病理生物学特征。
- 12个月随访时,淋巴-髓系病理类型患者需生物制剂的比例显著更高。
- 整合滑膜病理生物学标志物后,生物制剂需求临床预测模型性能从78.8%提升至89%-90%。
关键数值与推荐
- 患者按RA1987 ACR标准或UA分类,UA再按RA2010 ACR/EULAR标准分类。
- 滑膜病理类型分为淋巴-髓系、弥漫-髓系或寡免疫三类。
临床怎么用
- 对早期关节炎患者,滑膜活检病理分型可辅助识别需生物制剂的高风险患者。
- 将滑膜病理生物学标志物整合入临床预测模型可提升生物制剂需求预测性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To establish whether synovial pathobiology improves current clinical classification and prognostic algorithms in early inflammatory arthritis and identify predictors of subsequent biological therapy requirement. METHODS: 200 treatment-naïve patients with early arthritis were classified as fulfilling RA1987 American College of Rheumatology (ACR) criteria (RA1987) or as undifferentiated arthritis (UA) and patients with UA further classified into those fulfilling RA2010 ACR/European League Against Rheumatism (EULAR) criteria. Treatment requirements at 12 months (Conventional Synthetic Disease Modifying Antirheumatic Drugs (csDMARDs) vs biologics vs no-csDMARDs treatment) were determined. Synovial tissue was retrieved by minimally invasive, ultrasound-guided biopsy and underwent processing for immunohistochemical (IHC) and molecular characterisation. Samples were analysed for macrophage, plasma-cell and B-cells and T-cells markers, pathotype classification (lympho-myeloid, diffuse-myeloid or pauci-immune) by IHC and gene expression profiling by Nanostring. RESULTS: 128/200 patients were classified as RA1987, 25 as RA2010 and 47 as UA. Patients classified as RA1987 criteria had significantly higher levels of disease activity, histological synovitis, degree of immune cell infiltration and differential upregulation of genes involved in B and T cell activation/function compared with RA2010 or UA, which shared similar clinical and pathobiological features. At 12-month follow-up, a significantly higher proportion of patients classified as lympho-myeloid pathotype required biological therapy. Performance of a clinical prediction model for biological therapy requirement was improved by the integration of synovial pathobiological markers from 78.8% to 89%-90%. CONCLUSION: The capacity to refine early clinical classification criteria through synovial pathobiological markers offers the potential to predict disease outcome and stratify therapeutic intervention to patients most in need.
引用
- Lliso-Ribera G, Humby F, Lewis M, et al. Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Ann Rheum Dis. 2019. PMID: 31582377. doi:10.1136/annrheumdis-2019-215751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。